Highlights Genmab A/S BOERSE MUENCHEN

Equities

GE9

DK0010272202

Market Closed - BOERSE MUENCHEN Other stock markets 01:13:31 29/06/2024 am IST			5-day change	1st Jan Change
234.2 ^EUR	-2.21%		-3.94%	-18.82%

28/06	Would you like some more inflation?
28/06	Genmab, AbbVie's Lymphoma Therapy Recommended for Approval in EU	MT

Highlights

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Genmab, AbbVie's Lymphoma Therapy Recommended for Approval in EU	28/06	MT
AbbVie, Genmab Receive Positive European Opinion on Marketing Authorization for Possible Lymphoma Treatment	28/06	MT
AbbVie Receives Positive CHMP Opinion for Epcoritamab for the Treatment of Adults with Relapsed/Refractory Follicular Lymphoma	28/06	CI
Genmab Closes DKK3.5 Billion Share Buyback Early	28/06	MT
Genmab Gets FDA Approval for Follicular Lymphoma Treatment	27/06	MT
Genmab Wins US Approval for Follicular Lymphoma Treatment	27/06	MT
Genmab A/S Announces That the U.S. Food and Drug Administration Approved Epkinly® (Epcoritamab-Bysp) for the Treatment of Adults with Relapsed or Refractory Follicular Lymphoma After Two or More Lines of Systemic EPKINLY	27/06	CI
U.S. Food and Drug Administration Grants Second Approval for AbbVie's EPKINLY (epcoritamab-bysp) to Treat Patients with Relapsed or Refractory Follicular Lymphoma	27/06	CI
Genmab's Tisotumab Shows 'Encouraging' Antitumor Activity in Phase 2 Head, Neck Cancer Study	03/06	MT
Genmab A/S Announces Data from the Phase 2 Innovatv 207 Trial, Investigating Tisotumab Vedotin	03/06	CI
Genmab A S and BioNTech SE Announces Initial Data from the Ongoing Phase 2 Trial	03/06	CI
Genmab Announces Initial Data from Phase 2 Cancer Treatment Trial	03/06	MT
Genmab A/S Announces New Efficacy and Safety Data from Two Ongoing Phase 1/2 Clinical Trials Evaluating Epcoritamab, A T-Cell Engaging Bispecific Antibody Administered Subcutaneously, in Adult Patients with Certain Types of Follicular Lymphoma	03/06	CI
Genmab A/S and Biontech SE Announce Initial Data from the Phase 2 Gct1046-04 Trial (NCT05117242) Evaluating Acasunlimab	01/06	CI
Genmab A/S Reaffirms Financial Guidance for 2024	21/05	CI
Genmab A/S completed the acquisition of ProfoundBio, Inc.	21/05	CI
Genmab CEO Says Western Firms Should Tap Into China's 'Impressive Innovation'	15/05	MT
Genmab A/S to Present New and Updated Results from Multiple Clinical Trials Evaluating Epcoritamab Across Various B-Cell Malignancies At the 2024 European Hematology Association Congress	14/05	CI
GENMAB : A good start to 2024; guidance unchanged	03/05
Genmab Posts Q1 Net Profit Surge; Revenue Jumps	03/05	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Headlines

GENMAB : A good start to 2024; guidance unchanged

May 03, 2024 at 10:38 pm IST